Are the Immunohistochemistry-Based Biomarkers Helpful for Predicting Prognosis in Patients with Surgically Resected Cholangiocarcinoma?
作者信息
Kim Dong Uk
机构信息
Department of Internal Medicine, Pusan National University College of Medicine and Biomedical Research Center, Pusan National University Hospital, Busan, Korea.
出版信息
Gut Liver. 2023 Jan 15;17(1):10-11. doi: 10.5009/gnl220542.
Abstract
摘要
相似文献
1
Are the Immunohistochemistry-Based Biomarkers Helpful for Predicting Prognosis in Patients with Surgically Resected Cholangiocarcinoma?
Gut Liver. 2023 Jan 15;17(1):10-11. doi: 10.5009/gnl220542.
2
Cholangiocarcinoma Heterogeneity Revealed by Multigene Mutational Profiling: Clinical and Prognostic Relevance in Surgically Resected Patients.
Ann Surg Oncol. 2016 May;23(5):1699-707. doi: 10.1245/s10434-015-5046-6. Epub 2015 Dec 30.
3
Intrahepatic cholangiocarcinoma in Korea.
J Hepatobiliary Pancreat Surg. 1999;6(2):142-8. doi: 10.1007/s005340050097.
4
Intrahepatic recurrence after surgery in patients with intrahepatic cholangiocarcinoma.
J Gastroenterol. 2006 Sep;41(9):925-6. doi: 10.1007/s00535-006-1901-3.
5
[Surgical treatment for intrahepatic cholangiocarcinoma].
Nihon Rinsho. 2006 Jan;64 Suppl 1:469-75.
6
Clear cell cholangiocarcinoma of the liver is a morphologically distinctive entity.
Hum Pathol. 1998 Dec;29(12):1548-9. doi: 10.1016/s0046-8177(98)90031-4.
7
Prognostic significance of NQO1 expression in intrahepatic cholangiocarcinoma.
Int J Clin Exp Pathol. 2011 Apr;4(4):363-70. Epub 2011 Apr 10.
8
Extrahepatic cholangiocarcinoma: current surgical strategy.
Surg Oncol Clin N Am. 2009 Apr;18(2):269-88, viii. doi: 10.1016/j.soc.2008.12.003.
9
Intrahepatic cholangiocarcinoma.
Ann Surg. 2009 Mar;249(3):541-2; author reply 542. doi: 10.1097/SLA.0b013e31819aa76e.
10
Outcomes of surgery for 2010 WHO classification-based intraductal papillary neoplasm of the bile duct: Case-control study of a single Japanese institution's experience with special attention to mucin expression patterns.
Eur J Surg Oncol. 2019 May;45(5):761-768. doi: 10.1016/j.ejso.2018.10.532. Epub 2018 Oct 24.
本文引用的文献
1
Postoperative Prognostic Predictors of Bile Duct Cancers: Clinical Analysis and Immunoassays of Tissue Microarrays.
Gut Liver. 2023 Jan 15;17(1):159-169. doi: 10.5009/gnl220044. Epub 2022 Nov 1.
2
Molecular classification and therapeutic targets in extrahepatic cholangiocarcinoma.
J Hepatol. 2020 Aug;73(2):315-327. doi: 10.1016/j.jhep.2020.03.008. Epub 2020 Mar 12.
3
Histopathology-based immunoscore predicts recurrence for intrahepatic cholangiocarcinoma after hepatectomy.
Cancer Immunol Immunother. 2019 Aug;68(8):1369-1378. doi: 10.1007/s00262-019-02371-3. Epub 2019 Jul 23.
4
Prognostic biomarkers in patients with resected cholangiocarcinoma: a systematic review and meta-analysis.
Ann Surg Oncol. 2014 Feb;21(2):487-500. doi: 10.1245/s10434-013-3286-x. Epub 2013 Oct 1.
5
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.
Ann Surg. 2007 May;245(5):755-62. doi: 10.1097/01.sla.0000251366.62632.d3.
Zotero 插件